Stay updated with breaking news from Rachel Eides. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D) - read this article along with other careers information, tips and advice on BioSpace
Press release content from Globe Newswire. The AP news staff was not involved in its creation. CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel ... CRISPR Therapeutics AGApril 10, 2021 GMT ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company’s allogeneic chimeric antigen receptor T cell (CAR-T) program at the American Association for Ca...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer ... CRISPR Therapeutics AGMarch 10, 2021 GMT ZUG, Switzerland and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from A...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day CRISPR Therapeutics AGFebruary 5, 2021 GMT ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, Februa...
Cerevel Therapeutics to Host Inaugural Virtual R&D Event Cerevel Therapeutics to Host Inaugural Virtual R&D Event Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs Live webcast scheduled for Thursday, January 28 from 9:00 to 11:00 a.m. EST CAMBRIDGE, Mass., Dec. 14, 2020 — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host the first in a series of virtual R&D events on Thursday, January 28 from 9:00 to 11:00 a...